Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan

Diagnostic Microbiology and Infectious Disease

Volumn 43, Issue 2, 2002, Pages 141-147

  Sheng, Wang Huei ^a   Chen, Yee Chun ^a   Wang, Jann Tay ^a   Chang, Shan Chwen ^b   Luh, Kwen Tay ^a   Hsieh, Wei Chuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antimicrobial activity; Fluoroquinolones; Gram negative bacteria; Minimum inhibitory concentration

Indexed keywords

CIPROFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; SERRATIA MARCESCENS; SPECIES DIFFERENCE; STEADY STATE; TAIWAN; TEACHING HOSPITAL;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; TAIWAN; TIME FACTORS;

EID: 0036092815     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00381-4     Document Type: Article

References (46)

1. The clinical problems of bacterial resistance to the new quinolones
2. Trends in bacterial resistance to fluoroquinolones
3. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy
4. The quinolones: History and overview action and bacterial killing
5. Cross-resistance and cross susceptibility between fluoroquinolone agents
6. Prevalence of bacterial resistance to quinolones and other antimicrobial among avian Escherichia coli strains isolates from septicemic and healthy chickens in Spain
7. Analysis of 1186 episodes of gram-negative bacteremia in non-university hospitals: The effects of antimicrobial therapy
8. Fluoroquinolone resistance among methicillin-resistant staphylococci after usage of fluoroquinolones other than ciprofloxacin in Taiwan
9. Macrolide resistance of common bacteria isolated from Taiwan
10. Current status of bacterial antibiotic resistance in Taiwan
11. Antibiotic usage in public hospitals in Taiwan
12. High prevalence of antibiotic resistance of common pathogenic bacteria in Taiwan. The Antibiotic Resistance Study Group of the Infectious Disease Society of the Republic of China
13. Klebsiella pneumoniae isolates causing liver abscess in Taiwan
14. Antibiotic use in public hospitals in Taiwan after the implementation of National Health Insurance
15. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections
16. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone
17. Cross-resistance to fluoroquinolones in multiple-antibiotic resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: Decreased drug accumulation associated with membrane changes in addition to OmpF reduction
18. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli
19. Contribution of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli isolated from human and animals
20. In vitro activity of Bay y3118, a new quinolone
21. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone
22. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998
23. Emergence and dissemination of quinolone-resistance Escherichia coli in the community
24. Surveillance of antibiotic resistance in Taiwan, 1998
25. Bacterial resistance to the quinolone antimicrobial agents
26. Fluoroquinolone antimicrobial agents
27. Mechanisms of bacterial resistance to quinolones
28. Fluoroquinolone resistance: An evolving national problem or just a problem for some physician?
29. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus
30. Epidemiology and clinical impact of gram-negative sepsis
31. Reduced susceptibility to fluoroquinolones of Escherichia coli and Salmonella spp. isolated from retail chicken carcasses and emerging human resistance in Taiwan
32. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8796 clinical bacterial isolates
33. An outbreak of multidrug-resistant, quinolone-resistance Salmonella enterica serotye typhimurium DT 104
34. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones
35. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone
36. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
37. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections
38. Resistance to quinolones and fluoroquinolones
39. Fluoroquinolone resistance
40. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998
41. Antimicrobial activity of DV-7751a, a new fluoroquinolone
42. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis criteria for bacterial strain typing
43. In vitro studies with five quinolones: Evidence for changes in relative potency as quinolone resistance rises
44. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones
45. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone
46. Fluoroquinolone antimicrobial agents